Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies (NCT06652633)
A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies
🩺 Plain-English Summary (8th-Grade Level)
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion. Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all participants exposed to GLPG CAR T-cell therapies for 15 years following their last CAR T-cell infusion to assess the risk of delayed adverse events (AEs) and the long-term benefit/risk profile and to monitor for replication-competent lentivirus (RCL) and CAR-T cell persistence.
Who can join: Review the eligibility criteria below.
Location: Tufts Medical Center — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
- GLPG CAR T-cell therapy (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Tufts Medical Center — Boston, Massachusetts
- Antwerp University Hospital — Edegem,
- Universitair Ziekenhuis Leuven — Leuven,
- Centre Hospitalier Universitaire (CHU) De Liège — Liège,
- Algemeen Ziekenhuis Delta — Roeselare,
- Cliniques Universitaires Saint-Luc — Woluwe-Saint-Lambert,
- helsingin yliopistollinen sairaala comprehensive cancer center (HUS) — Helsinki,
- Academisch Medisch Centrum (Amsterdam UMC) — Amsterdam,
- Leids University Medical Center (LUMC) — Leiden,
- Erasmus Medisch Centrum — Rotterdam,
- Hospital Clinic De Barcelona — Barcelona,
📞 Contact the Study Coordinator
Phone: (321) 534-2900
Email: medicalinfo@lakefrontbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancies
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — Houston, Texas
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Hematological Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.